Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

Larimar Therapeutics, Inc.

Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.
Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.
FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.
Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Larimar Therapeutics, Inc. reported the fourth quarter of 2025 and for the year ended December 31, 2025 results: net income $62.5 million, or $0.73 per share of common stock.

Period: the fourth quarter of 2025 and for the year ended December 31, 2025
Net income: $62.5 million, or $0.73 per share of common stock
Result: reported results

Exact text from the filing

On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-115119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.